| Comprehensive molecular portraits of human breast tumours Brigham & Women’s Hospital & Harvard Medical School Chin Lynda 9 11 Park ... Nature 490 (7418), 61-70, 2012 | 11728 | 2012 |
| Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer A Prat, JS Parker, O Karginova, C Fan, C Livasy, JI Herschkowitz, X He, ... Breast cancer research 12, 1-18, 2010 | 2907 | 2010 |
| Deconstructing the molecular portraits of breast cancer A Prat, CM Perou Molecular oncology 5 (1), 5-23, 2011 | 1915 | 2011 |
| Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer S Modi, W Jacot, T Yamashita, J Sohn, M Vidal, E Tokunaga, J Tsurutani, ... New England Journal of Medicine 387 (1), 9-20, 2022 | 1848 | 2022 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised … E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ... The lancet oncology 18 (9), 1274-1284, 2017 | 1819 | 2017 |
| 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4) F Cardoso, E Senkus, A Costa, E Papadopoulos, M Aapro, F André, ... Annals of Oncology 29 (8), 1634-1657, 2018 | 1315 | 2018 |
| Clinical implications of the intrinsic molecular subtypes of breast cancer A Prat, E Pineda, B Adamo, P Galván, A Fernández, L Gaba, M Díez, ... The Breast 24, S26-S35, 2015 | 1310 | 2015 |
| Immune-related adverse events of checkpoint inhibitors M Ramos-Casals, JR Brahmer, MK Callahan, A Flores-Chávez, N Keegan, ... Nature reviews Disease primers 6 (1), 38, 2020 | 1110 | 2020 |
| Prognostic significance of progesterone receptor–positive tumor cells within immunohistochemically defined luminal A breast cancer A Prat, MCU Cheang, M Martín, JS Parker, E Carrasco, R Caballero, ... Journal of clinical oncology 31 (2), 203-209, 2013 | 791 | 2013 |
| Molecular characterization of basal‐like and non‐basal‐like triple‐negative breast cancer A Prat, B Adamo, MCU Cheang, CK Anders, LA Carey, CM Perou The oncologist 18 (2), 123-133, 2013 | 752 | 2013 |
| Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts S Li, D Shen, J Shao, R Crowder, W Liu, A Prat, X He, S Liu, J Hoog, C Lu, ... Cell reports 4 (6), 1116-1130, 2013 | 717 | 2013 |
| Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–rich stage 2 to 3 breast cancer … MJ Ellis, VJ Suman, J Hoog, L Lin, J Snider, A Prat, JS Parker, J Luo, ... Journal of clinical oncology 29 (17), 2342-2349, 2011 | 693 | 2011 |
| Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 HJ Burstein, G Curigliano, B Thürlimann, WP Weber, P Poortmans, ... Annals of oncology 32 (10), 1216-1235, 2021 | 660 | 2021 |
| PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition YH Ibrahim, C García-García, V Serra, L He, K Torres-Lockhart, A Prat, ... Cancer discovery 2 (11), 1036-1047, 2012 | 630 | 2012 |
| A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models X Zhang, S Claerhout, A Prat, LE Dobrolecki, I Petrovic, Q Lai, MD Landis, ... Cancer research 73 (15), 4885-4897, 2013 | 547 | 2013 |
| Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer F Schettini, N Chic, F Brasó-Maristany, L Paré, T Pascual, B Conte, ... NPJ breast cancer 7 (1), 1, 2021 | 504 | 2021 |
| Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor–positive, human epidermal growth factor receptor 2–negative … FC Bidard, VG Kaklamani, P Neven, G Streich, AJ Montero, F Forget, ... Journal of Clinical Oncology 40 (28), 3246-3256, 2022 | 480 | 2022 |
| USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma PJA Eichhorn, L Rodón, A Gonzàlez-Juncà, A Dirac, M Gili, ... Nature medicine 18 (3), 429-435, 2012 | 446 | 2012 |
| PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers RRL Bastien, Á Rodríguez-Lescure, MTW Ebbert, A Prat, B Munárriz, ... BMC medical genomics 5, 1-12, 2012 | 426 | 2012 |
| Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors R Dienstmann, J Rodon, A Prat, J Perez-Garcia, B Adamo, E Felip, ... Annals of oncology 25 (3), 552-563, 2014 | 420 | 2014 |